1.
Baseline demographic and clinical data of the patients
| Variable | All patients |
| n | 54 |
| Age at onset (year) | 25(18.75-33.25) |
| Male/female (n) | 36/18 |
| Disease location (n) | |
| Terminal ileum | 15 |
| Colon | 13 |
| Ileocolon | 26 |
| Upper gastrointestinal tract | 0 |
| Age at diagnosis (year) | 25 (19.75-26) |
| Age at start of IFX (year) | 26 (20-36) |
| Duration from diagnosis to infliximab therapy (month) | 17(2-144) |
| Duration from onset to infliximab therapy (month) | 34 (3-180) |
| Concomitant therapies [n (%)] | |
| Mesalamine | 38 (70.3%) |
| Corticosteroids | 4 (7.4%) |
| Immunomodulators | 17(31.5%) |
| Hemoglobin (g/dL) | 125 (109-141) |
| Albumin (g/dL) | 42 (38.65-45.85) |
| C-reactive protein (mg/dL) | 3.9 (1.2-22.7) |
| Neutrophil-lymphocyte ratio | 2.07 (1.34-3.26) |
| Mean platelet volume (fl) | 8.3 (7.5-9.5) |
| Infliximab (mg/kg) | 4.63 (4.33-5.26) |